Active Arthritis Studies

We are constantly seeking participants for a number of studies. Please apply to any studies for which you may qualify, or call us at (417) 883-7889 for more information!

If You Suffer from Arthritis, Clinvest Is Here to Help

Aching fingers, painful knees, and overall joint stiffness can lock up your lifestyle. Join a Clinvest Research study to help advance medical knowledge of an array of arthritic conditions including Rheumatoid Arthritis, Psoriatic Arthritis, Giant Cell Arteritis, and Ankylosing Spondylitis.

Clinvest knows how challenging and frustrating arthritis difficulties can be. We have a strong commitment to further treatment through specialized research studies including: Rheumatoid, Psoriatic, Giant Cell Arteritis, and Ankylosing Spondylitis. We partner with pharmaceutical companies in an effort to discover solutions for such debilitating conditions and look forward to the new horizons in health and well-being.

    Psoriatic Arthritis Research Study

    Abbvie M15-998

    The purpose of this study is to evaluate the efficacy and safety of risankizumab 150 mg for the potential treatment of signs and symptoms of psoriatic arthritis (PsA) in subjects with moderately to severely active PsA who do not respond to treatment after at least 12 weeks of therapy or for subjects who cannot take 1 or more conventional synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARD) or biologic therapies. The study is up to 233 weeks, 26 visits.

    Duration: 4.5 Years

    Number: 27

    Giant Cell Arteritis Study

    Abbvie M16-852

    Eligible subjects over 50 years in age who have been newly diagnosed or have relapsing Giant Cell Arteritis. Participants will be randomized to receive either standard of care or investigational product in addition to standard of care for up to two years over 21 visits. Your first appointment would last approximately 2 hours. If you qualify and choose to volunteer, we would provide investigational study pills, or standard of care pills and all study-related procedures at no cost to you (including basic study-related physical exams, bloodwork, ECG’s, and urine drug/pregnancy tests). Compensation may be provided for your time and travel.

    Duration: Up to 2 Years

    Number: 21

    Ankylosing Spondylitis

    CAIN457FUS06

    The purpose of this study is to determine the benefit of taking 300mg of an investigational drug compared to the currently approved 150mg dose for patients with Ankylosing Spondylitis (AS). Qualifying volunteers would come to our office for approximately 19 visits over a 52-week period. Patients will be given 16 doses of the investigational drug during the course of the study.

    Duration: 52 Weeks

    Number: 19

Want to find out when new studies are available?

Fill out the form!